NEW YORK, Oct. 4, 2019 /PRNewswire/ -- WeissLaw LLP is
investigating possible breaches of fiduciary duty and other
violations of law by the Board of Dova Pharmaceuticals, Inc.
("Dova" or the "Company") (NASDAQ: DOVA) in connection with the
proposed acquisition of the Company by Swedish Orphan Biovitrum AB
("Sobi") (OM: SOBI). Under the terms of the acquisition
agreement, DOVA shareholders will receive $27.50 in cash and a contingent value right
entitling each DOVA shareholder to an additional $1.50 upon regulatory approval of DOPTELET, the
Company's treatment for chemotherapy-induced
thrombocytopenia.
If you own DOVA shares and wish to discuss
this investigation or have any questions concerning this notice or
your rights or interests, visit our website: please
contact:
http://www.weisslawllp.com/dova-pharmaceuticals-inc/
Or please contact:
Joshua Rubin,
Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
WeissLaw is investigating whether Dova's Board acted to maximize
shareholder value prior to entering into the acquisition
agreement. Notably, at least one analyst set a target price
of $32.00 per DOVA, or $4.50 over the per-share offer price.
In addition, according to the announcement, the acquisition will
enhance Sobi's position as a leader in hematology and orphan
diseases, and expand its footprint in the United States.
Given these facts, WeissLaw is concerned whether the proposed
acquisition undervalues the Company, and whether all material
information related to the proposed acquisition is fully and fairly
disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-dova-pharmaceuticals-inc-300931486.html
SOURCE WeissLaw LLP